Renal Failure Treatment Market To Reach $197.1 Billion By 2030

Renal Failure Treatment Market Growth & Trends

The global renal failure treatment market size is anticipated to reach USD 197.1 billion by 2030 and is anticipated to grow at a CAGR of 8.3% from 2024 to 2030, according to a new report by Grand View Research, Inc. The market encompasses a range of products and services designed to manage and treat chronic kidney disease (CKD) and end-stage renal disease (ESRD).

The increasing prevalence of chronic kidney disease is a significant market driver. The growing incidence is largely attributed to the rising rates of diabetes and hypertension, which are known risk factors for kidney disease. As the population ages and these chronic conditions become more prevalent, the need for renal failure treatment continues to grow, placing additional pressure on healthcare systems to provide adequate care.

Rising awareness and education about kidney health are crucial market drivers. Public health campaigns and initiatives aimed at educating individuals about the risks and symptoms of kidney disease have contributed to earlier diagnosis and treatment. The heightened awareness encourages patients to seek medical advice sooner, ultimately leading to timely interventions and improved management of kidney conditions.

In October 2023, Zydus Lifesciences Limited and Sun Pharmaceutical Industries Limited (Sun Pharma) entered a licensing agreement to co-commercialize Desidustat, the first oral drug in India to treat anemia caused by chronic kidney disease (CKD). The licensing agreement for Desidustat represents a significant development in the market by providing a novel oral treatment option for anemia associated with CKD, enhancing patient care, and expanding market access in India.

 Request a free sample copy or view report summary: Renal Failure Treatment Market Report

Renal Failure Treatment Market Report Highlights

• Based on treatment, dialysis dominated the market with the largest revenue share of 72.34% in 2023. The rising prevalence of CKD and ESRD is driving the demand for renal replacement therapies. Major factors contributing to this trend include an aging population, technological advancements in dialysis, and increased kidney health awareness

• Based on end-use, hospitals dominated the market with the largest revenue share of 57.64% in 2023. Factors driving this growth include a rise in patient admissions for dialysis and transplant procedures, technological advancements in renal care equipment, and comprehensive healthcare services provided by hospitals that cater to complex cases

Renal Failure Treatment Market Segmentation

Grand View Research has segmented the global renal failure treatment market based on treatment, end-use, and region:

Renal Failure Treatment Outlook (Revenue, USD Million, 2018 - 2030)

• Dialysis

  • Hemodialysis

  • Peritoneal Dialysis

• Kidney Transplantation

• Drug Therapy

  • Antihypertensive Drugs

  • Antianemia Therapeutics (Erythropoiesis-Stimulating Agents)

  • Potassium Binders

  • Phosphate Binders

• Others

Renal Failure End-use Outlook (Revenue, USD Million, 2018 - 2030)

• Hospitals

• Specialty Clinics

• Others

Renal Failure Regional Outlook (Revenue, USD Million, 2018 - 2030)

• North America

  • U.S.

  • Canada

  • Mexico

• Europe

  • Germany

  • UK

  • France

  • Italy

  • Spain

  • Denmark

  • Sweden

  • Norway

• Asia Pacific

  • China

  • Japan

  • India

  • South Korea

  • Australia

  • Thailand

• Latin America

  • Brazil

  • Argentina

• Middle East and Africa (MEA)

  • South Africa

  • Saudi Arabia

  • UAE

  • Kuwait

List of Key Players in the Renal Failure Treatment Market

• NIPRO

• Fresenius Medical Care AG,

• Baxter

• Medtronic

• B. Braun SE

• Asahi Kasei Medical Co., Ltd.

• AbbVie Inc.

• Nikkiso Co., Ltd.

• JMS Co., Ltd.

• AstraZeneca